TherapeuticsMD (TXMD) Reports Q4 Loss of $0.10/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Noble Financial Lifts PT on TherapeuticsMD (TXMD) to $15; Sees Reduced TX 12-001HR Risk
March 11, 2015 11:47 AM EDTNoble Financial affirms TherapeuticsMD, Inc. (AMEX: TXMD) at Buy and nudges its price target from $14 up to $15 following Q4 results and update issued after markets closed Tuesday.
Analyst Nathan Cali noted that the bump higher in TXMD's price target stems from an increased cash balance, lowering the cost of capital by 5 points to 15 percent, and increasing risk-adjusted rNPV for TX 12-001HR, bioidentical estradiol/progesterone.
Cali also noted the following key points from the quarter and recent updates:
March 10th, 2015 reported relatively inline full year 2015 financial... More